

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nai-Kong V. CHEUNG
U.S. Serial No. : 10/565,484
Confirmation No. : 2140
Filed : January 17, 2006
Examiner : Eric Olson
Art Unit : 1623
For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

October 10, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with his duty of disclosure under 37 C.F.R. §1.56, Applicant would like to direct the Examiner's attention to the following references which are also listed on Forms PTO/SB/08A and PTO/SB/08B (attached hereto as **Exhibit A**). References 67, 70, 75-76, 81-83, 88-90, 93, 95-96, 98-99, 105, 107-108, 110-118, 122, 127, 130 and 132-133 are further attached respectively as **Exhibits 1-32**.

The U.S. Patents listed (References 1-24) and the U.S. Application Publications listed (References 25-36) are on file at the USPTO; therefore, in accordance with 37 C.F.R. 1.98, copies of these references are not provided. However, the office of the Applicant's

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: October 10, 2008
Examiner	: Eric Olson		
Page	: 2		

attorney may be contacted in the event that the Examiner would like a copy of any of references 1-36.

Copies of the References 37, 47, 52 and 56-57 were previously submitted in a related application on June 6, 2008 (U.S. Serial No. 10/621,027, Atty. Dkt. #639-B-PCT-US) and are available at the USPTO; therefore, copies of these references are not provided. The office of the Applicant's attorney may be contacted in the event that the Examiner would like a copy of these references.

Copies of the References 53-55, 74, 87, 102, 123 and 131 were previously submitted in a related application on December 26, 2007 (U.S. Serial No. 11/218,044, Atty. Dkt. #639-BZ-PCT-US) and are available at the USPTO; therefore, copies of these references are not provided. The office of the Applicant's attorney may be contacted in the event that the Examiner would like a copy of these references.

Copies of the References 40-46, 48-51, 68-69, 71-72, 78-80, 84-86, 91-92, 97, 101, 104, 119-120, 124-126 and 128 were previously submitted in a related application on December 17, 2007 (U.S. Serial No. 10/621,027, Atty. Dkt. #639-B-PCT-US) and are available at the USPTO; therefore, copies of these references are not provided. The office of the Applicant's attorney may be contacted in the event that the Examiner would like a copy of these references.

Copies of the References 59-60 and 63-65 were previously submitted in a related application on November 5, 2007 (U.S. Serial No. 11/218,044, Atty. Dkt. #639-BZ-PCT-US) and are available at the USPTO; therefore, copies of these references are not provided. The office of the Applicant's attorney may be contacted in the event that the Examiner would like a copy of these references.

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: October 10, 2008
Examiner	: Eric Olson		
Page	: 3		

Copies of the References 38-39, 58, 61-62, 66, 73, 77, 94, 100, 103, 106, 109, 121, 129 and 134 were previously submitted in a related application on October 26, 2007 (U.S. Serial No. 10/621,027, Atty. Dkt. #639-B-PCT-US) and are available at the USPTO; therefore, copies of these references are not provided. The office of the Applicant's attorney may be contacted in the event that the Examiner would like a copy of these references.

1. U.S. Patent No. 7,030,101, April 18, 2006, PAVLIAK et al., "Compositions of β -Glucans and Specific Antibodies."
2. U.S. Patent No. 6,143,731, November 7, 2000, JAMAS et al., "Glucan Dietary Additives."
3. U.S. Patent No. 6,117,850, September 12, 2000, PATCHEN et al., "Mobilization of Peripheral Blood Precursor Cells by $\beta(1,3)$ -Glucan."
4. U.S. Patent No. 6,020,324, February 1, 2000, JAMAS et al., "Glucan Dietary Additives."
5. U.S. Patent No. 5,817,643, October 6, 1998, JAMAS et al., "Underivatized, Aqueous Soluble $\beta(1,3)$ Glucan, Composition and Method of Making Same."
6. U.S. Patent No. 5,811,542, September 22, 1998, JAMAS et al., "Method for producing Soluble Glucans."
7. U.S. Patent No. 5,804,199, September 8, 1998, AASJORD et al., "Oil-Based and Water-Based Adjuvant Mixture."
8. U.S. Patent No. 5,783,569, July 21, 1998, JAMAS et al., "Uses for Underivatized, Aqueous Soluble $\beta(1-3)$ Glucan and Compositions Comprising Same."

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: October 10, 2008
Examiner	: Eric Olson		
Page	: 4		

9. U.S. Patent No. 5,726,023, March 10, 1998, CHEEVER et al., "Immune Reactivity to HER-2/NEU Protein for Diagnosis and Treatment of Malignancies in which the HER-2/NEU Oncogene is Associated."
10. U.S. Patent No. 5,702,719, December 30, 1997, BYRON A. DONZIS, "Substantially Purified Beta (1,3) Finely Ground Yeast Cell Wall Glucan Composition with Dermatological and Nutritional Uses."
11. U.S. Patent No. 5,696,079, December 9, 1997, LANE et al., "Immunologic Enhancement Interleukin-2 Therapy."
12. U.S. Patent No. 5,622,940, April 22, 1997, OSTROFF, Gary, "Inhibition of Infection-Stimulated Oral Tissue Destruction by $\beta(1,3)$ -Glucan."
13. U.S. Patent No. 5,607,677, March 4, 1997, JAMAS et al., "Glucan Drug Delivery System and Adjuvant."
14. U.S. Patent No. 5,576,015, November 19, 1996, BYRON A. DONZIS, "Substantially Purified Beta (1,3) Finely Ground Yeast Cell Wall Glucan Composition With Dermatological and Nutritional Uses."
15. U.S. Patent No. 5,532,223, July 2, 1996, JAMAS et al., "Uses of Aqueous Soluble Glucan Preparations to Stimulate Platelet Production."
16. U.S. Patent No. 5,037,972, August 6, 1991, JAMAS et al., "Glucan Composition and Process for Preparation Thereof."

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 5

17. U.S. Patent No. 4,992,540, February 12, 1991, JAMAS et al.,
"Glucan Composition and Process for Preparation Thereof."
18. U.S. Patent No. 4,926,094, May 15, 1990, BONDESON et al.,
"High-Performance Gyrotron for Production of Electromagnetic
Millimeter or Submillimeter Waves."
19. U.S. Patent No. 4,900,722, February 13, 1990, WILLIAMS et al.,
"Methods and Compositions for Prophylactic and Therapeutic
Treatment of Infections."
20. U.S. Patent No. 4,705,780, November 10, 1987, MASSOT et
al., "Medicaments containing Pichia or Extracts Thereof."
21. U.S. Patent No. 4,454,289, June 12, 1984, NAKAJIMA et al.,
"Polysaccharides having Anticarcinogenic Activity and Method
for Producing Same."
22. U.S. Patent No. 4,343,784, August 10, 1982, MASSOT et
al., "Composition and Method Employing Extracts of
Hansenula as a Medicament."
23. U.S. Patent No. 4,251,519, February 17, 1981, ROBBINS et
al., "Process for the Prevention and Reduction of
Elevated Blood Cholesterol and Triglycerides Levels."
24. U.S. Patent No. 3,975,553, August 17, 1976, HENRI
GRIFFON, "Deproteination of Yeast Cells."
25. U.S. Application Publication 2007/134259, June 14, 2007,
BUNDLE et al., "Methods and Compositions for
Pharmacologically Controlled Targeted Immunotherapy"

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 6

26. U.S. Application Publication 2007/59310, March 15, 2007,
STEVEN J. KAREL, "Therapeutic Combination Compositions
and Methods of Using Same"
27. U.S. Application Publication 2007/20232, January 25,
2007, ROSSIGNOL et al., "Compositions and Methods for
Cancer Immunotherapy"
28. U.S. Application Publication 2007/263355, November 23,
2006, QUAN et al., "Treatment of Bone Disorders"
29. U.S. Application Publication 2006/165700, July 27, 2006,
OSTROFF et al., "Cancer Therapy Using Whole Glucan
Particles and Antibodies"
30. U.S. Application Publication 2006/160766, July 20, 2006,
NAI-KONG V. CHEUNG, "Therapy-Enhancing Glucan"
31. U.S. Publication No. US-2006-0020128, January 26, 2006,
Nai-Kong CHEUNG, "Therapy-Enhancing Glucan."
32. U.S. Application Publication 2006/09419, January 12,
2006, ROSS et al., "Therapy-Enhancing Glucan"
33. U.S. Application Publication 2005/208079, September 22,
2005, CASSONE et al., "Glucan-Based Vaccines"
34. U.S. Application Publication 2005/118187, June 2, 2005,
BAOFA YU, "Combinations and Methods for Treating
Neoplasms"
35. U.S. Application Publication 2002/119928, August 29,
2002, BILL H. MCANALLEY, "Dietary Supplement
Compositions"

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 7

36. U.S. Application Publication 2002/44919, April 18, 2002, BAOFA YU, "Combinations and Methods for Treating Neoplasms"
37. Supplementary Partial European Search Report, February 5, 2008, for European Application No. EP 02 70 7502, filed August 4, 2003 for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH.
38. PCT International Search Report for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, September 26, 2007, Int'l Application No. PCT/US07/01427 (Atty. Dkt. #639-F-PCT), Filed January 18, 2007.
39. PCT Written Opinion of the International Searching Authority for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, September 26, 2007, Int'l Application No. PCT/US07/01427 (Atty. Dkt. #639-F-PCT), Filed January 18, 2007.
40. International Publication No. WO 2007/84661, July 26, 2007, Sloan-Kettering Institute for Cancer Research, PCT/US2007/001427, "Therapy-Enhancing Glucan."
41. International Publication No. WO 2006/119395, November 9, 2006, Biopolymer Engineering, PCT/US2006/017065 "Combination of a Beta-Glucan and an EGF Receptor antagonist for the Treatment of Cancer and Infection."
42. International Publication No. WO 2006/85895, August 17, 2006, BIOPOLYMER ENGINEERING INC (US) and UNIV LOUISVILLE RES FOUNDATION (US), "Whole Glucan Particles in Combination with Antibiotics, Vaccines and Viral Monoclonal Antibodies."

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: October 10, 2008
Examiner	: Eric Olson		
Page	: 8		

43. International Publication No. WO 2005/49044, June 2, 2005, Laboratoires Goemar SA, PCT/EP2004/013119, "Oligo-Beta-(1,3) -Glucan and Monoclonal Antibodies Against Cancer."
44. International Publication No. WO 2005/27938, March 31, 2005, Laboratoires Goemar SA, PCT/EP2004/010993, "Chemotherapeutic Antineoplastic Treatment."
45. International Publication No. WO 2005/27936, March 31, 2005, Laboratoires Goemar SA, PCT/EP2004/010995, "Pharmaceutical Compositions and Therapeutical Treatment with Oligo-Beta-(1,3)-Glucans."
46. International Publication No. WO 2004/30613, March 16, 2004, University of Louisville Research Foundation, Inc., PCT/US2003/027975, "Cancer Therapy Using Beta Glucan and Antibodies."
47. International Publication No. WO 2003/54077, July 3, 2003, Ceapro Inc., PCT/CA2002/001896, "Cereal Beta Glucan Compositions, Methods of Preparation and Uses Thereof."
48. International Publication No. WO 2003/004507, January 16, 2003, Research Center for Eco-Environmental Sciences, Academia Sinica, PCT/CN2002/000478, "A Kind of Oligosaccharides, their sulfates and Dendrimers, and the Uses of these Compounds."
49. International Publication No. WO 2002/58711, August 1, 2002, Sloan-Kettering Institute for Cancer Research, PCT/US2002/001276, "Therapy-Enhancing Glucan."

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: October 10, 2008
Examiner	: Eric Olson		
Page	: 9		

50. International Publication No. WO 2001/80807, November 1, 2001, Laboratoires Goemar SA, PCT/FR2001/001323, "Medicine Containing Polysaccharide Substances for Activating Apoptosis."
51. International Publication No. WO 2001/68105, November 20, 2001, Eurand Pharmaceuticals Ltd., PCT/EP2001/003050, "Polysaccharidic Esters of N-Derivatives of Glutamic Acid."
52. International Publication No. WO 1999/52548, October 21, 1999, Lees et al., PCT/US1999/007828, "Conjugate Vaccines for the Prevention of Dental Caries."
53. International Publication No. WO 1991/03248, March 21, 1991, Alpha Beta Technology, Inc., PCT/US1990/005022, "Method for Immune System Activation."
54. European Publication No. EP 0463540A1, February 1, 1992, TAITO CO., et al., "Anti-virus agent."
55. German Patent No. DE 30 19 614 A1, December 3, 1981, MATSUEDA et al., "Hydrolyzed polysaccharide." (English abstract included)
56. Chinese Office Action, May 9, 2008, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Chinese Application No. 200480020356.6 (Atty. Dkt. #639-C-PCT-CN), Filed January 16, 2006, corresponding to PCT/US04/23099.
57. U.S. Office Action, March 5, 2008, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/334,763 (Atty. Dkt. #639-E-US), Filed January 17, 2006.

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 10

58. U.S. Office Action, August 7, 2007, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005. (Atty Dkt. #639-BZ-PCT-US).
59. U.S. Office Action, August 7, 2007, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).
60. U.S. Office Action, January 4, 2007, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).
61. U.S. Office Action, November 22, 2006, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005. (Atty. Dkt. #639-BZ-PCT-US).
62. U.S. Office Action, March 10, 2006, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005. (Atty. Dkt. #639-BZ-PCT-US).
63. U.S. Office Action, March 6, 2006, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).
64. U.S. Office Action, July 13, 2005, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).
65. U.S. Office Action, December 17, 2004, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003, (Atty. Dkt. #639-B-PCT-US).
66. Beta Glucan Health Center webpage, November 10, 2000, "PLEURAN- Beta-1,3/1-6-Glucan,"

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 11

<http://www.glucan.com/therapy/therapy.com>.

67. 1999 The Merck Manual of Diagnosis and Therapy, 397-398, 948-949, 1916, 1979-1981. (**EXHIBIT 1**)
68. ADACHI et al., 1990, "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)- β -D-Glucans", Chem. Pharm. Bull., 38(4):988-992.
69. AZUMA, Ichiro, "Development of Immunostimulants in Japan", Immunostimulants: Now and Tomorrow, 41-56.
70. BERGMAN et al., 1999, "Treatment of Neoplastic Meningeal Xenografts by Intraventricular Administration of an Antiganglioside Monoclonal Antibody, 3F8," Int. J. Cancer, 82:538-548 (**EXHIBIT 2**)
71. BLUHM et al., 1977, "The triple helical structure of lentinan, a linear β -(1-3)-D-glucan", Can J Chem, 55:293-299.
72. BOGWALD et al., 1982, "The Cytotoxic Effect of Mouse Macrophages Stimulated in Vitro by a β -1,3-D-Glucan from Yeast Cell Walls", Scandinavian Journal of Immunology, 15:297-304.
73. BOHN, J.A., and BeMiller, J.N., 1995, "(1-3)- β -Glucans as biological response modifiers: a review of structure-functional activity relationships," Carbohydrate Polymers, 28:3-14.
74. BOWERS et al., 1989, "Glucan Enhances Survival in an Intraabdominal Infection Model", Journal of Surgical Research, Vol 47(2):183-188.

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 12

75. CAPURRO et al., 1998, "FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis^x hapten," Cancer Immunol. Immunother., 45:334-339. (**EXHIBIT 3**)
76. CHEUNG, N.-K. V., et al., 2002, "Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcription-Polymerase Chain Reaction - Utility in Bone Marrow Purging of Neuroblastoma by Anti-GD2 Antibody 3F8," Cancer, 94:3042-3048. (**EXHIBIT 4**)
77. CHEUNG, N.-K. V., et al., June 1985, "Monoclonal Antibodies to a Glycolipid Antigen on Human Neuroblastoma Cells," Canc. Res., 45:2642-2649.
78. CHIHARA et al., 1970, "Fractionation and purification of the polysaccharides with Marked Antitumor Activity, Especially Lentinan, from Lentinus edodes (Berk.) Sing. (an Edible Mushroom)," Cancer Res, 30:2776-2781.
79. CHIHARA et al., 1981, "The antitumor polysaccharide Lentinan: an overview", Manipulation of Host Defence Mechanisms, 1-16.
80. CHIHARA et al., 1982, "Current Status and Perspectives of Immunomodulators of Microbial Origin", International Journal of Tissue Reactions, 4:207-225.
81. DAMGE et al., December 1996, "Intestinal absorption of PLAGA microspheres in the rat," J. Anat., 189:491-501 (**EXHIBIT 5**)

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 13

82. D'AMICO et al., 2000, "Molecular Biologic Substaging of Stage I Lung Cancer According to Gender and Histology," Ann. Thorac. Surg., 69:882-886. (**EXHIBIT 6**)
83. DAVID et al., 1996, "Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans," Nature Medicine, 2:686-689. (**EXHIBIT 7**)
84. DI LUZIO et al., 1985, "Glucans as Immunomodulators", Advances in Immunopharmacology, Permagon Press, NY, 369-375
85. DI LUZIO et al., 1980, "Comparative Evaluation of the Tumor Inhibitory and Antibacterial Activity of Solubilized and Particulate Glucan", Recent Results in Cancer Research, 75:165-172.
86. DI LUZIO, Nicholas R., 1985, "Update on the Immunomodulating Activities of Glucans", Springer Seminars in Immunopathology, 8:387-400.
87. DI LUZIO, Nicholas R., 2003, "Immunopharmacology of glucan: a broad spectrum enhancer of host defense mechanisms", T.I.P.S., 344-347.
88. ENGLER et al., April 1, 2001, "A Novel Metastatic Animal Model Reflecting the Clinical Appearance of Human Neuroblastoma: Growth Arrest of Orthotopic Tumors by Natural, Cytotoxic Human Immunoglobulin M Antibodies," Cancer Research 61:2968-2973. (**EXHIBIT 8**)
89. FLORENCE A., 1997, "The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual," Pharmaceutical Research, 14(3):259-266. (**EXHIBIT 9**)

Applicant	: Nai-Kong V. CHEUNG	Atty. Dkt. No.	: 639-C-PCT-US
USSN	: 10/565,484	Art Unit	: 1623
Filed	: January 17, 2006	Date of SIDS	: October 10, 2008
Examiner	: Eric Olson		
Page	: 14		

90. FURUE et al., 1985, "Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report): a randomized controlled study," Gan To Kagaku Ryoho, 12: 1272-1277. (**EXHIBIT 10**)
91. HAMURO et al., 1971, "The significance of the higher structure of the polysaccharides lentinan and pachymaran with regard to their antitumour activity", Chem. Biol. Interactions, 3:69-71.
92. HAMURO et al., 1978, "Solid phase activation of alternative pathway of complement by β -1,3-glucans and its possible role for tumour regressing activity", Immunology, 34:695-705.
93. HARADA et al., 1997, "Oral Administration of PSK can Improve the Impaired Anti-Tumor CD4⁺ T-Cell Response in Gut-Associated Lymphoid Tissue (GALT) of Specific-Pathogen-Free Mice," Int. J. Cancer, 70:362-372. (**EXHIBIT 11**)
94. HELLSTROM, I. et al., September 1986, "Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas," Proc. Natl. Acad. Sci. USA, 83:7059-7063.
95. HERRE et al., February 2004, "Dectin-1 and its role in the recognition of β -glucans by macrophages," Mol. Immunol. 40(12):869-876. (**EXHIBIT 12**)
96. HERRERA et al., 2000, "Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells *in vitro*," Leukemia, 14:853-858. (**EXHIBIT 13**)

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 15

97. JAMAS et al., 1990, "Spectral Analysis of Glucan Produced by Wild-Type and Mutant *Saccharomyces cerevisiae*", Carbohydrate Polymers, 13:207-219.
98. JANI et al., December 1990, "Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency," J. Pharm. Pharmacol., 42:821-826. (EXHIBIT 14)
99. KERNODLE et al., March 1998, "Prophylactic Anti-Infective Activity of Poly-[1-6]- β -D-Glucopyranosyl-[1-3]- β -D-Glucopyranose Glucan in a Guinea Pig Model of Staphylococcal Wound Infection," Antimicrobial Agents and Chemotherapy, 42(3):545-549. (EXHIBIT 15)
100. KIM, Y.-S., et al., October 20, 2000, "Gram-negative Bacteria-binding Protein, a Pattern Recognition Receptor for Lipopolysaccharide and β -1,3-Glucan That Mediates the Signaling for the Induction of Innate Immune Genes in *Drosophila melanogaster* Cells," J. Biol. Chem., 275(42):32721-32727.
101. KIRBY et al., 1981, "Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men", American Journal of Clinical Nutrition, 34:824-829.
102. KOMATSU et al., 1975, "Influence of Schizophyllan, Streptomycin and Rifampicin on Histopathological changes in mice infected with Tubercle Bacilli", Japanese Journal of Antibiotics, XXVII(4):549-557. (English abstract included)

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 16

- 103.KOTERA, Y., et al., June 1, 1994, "Humoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients," Cancer Res., 54:2856-2860.
- 104.MAEDA et al., 1971, "Lentinan, a new immune-accelerator of cell-mediated responses", Nature, 229:634.
- 105.MALONEY et al., September 15, 1997, "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195. (**EXHIBIT 16**)
- 106.MATZINGER, P., 1994, "Tolerance, Danger, and the Extended Family," Annu. Rev. Immunol., 12:991-1045.
- 107.MAYELL M, February 2001, "Maitake Extracts and Their Therapeutic Potential - A Review," Altern. Med. Rev., 6(1):48-60. (**EXHIBIT 17**)
- 108.MENDELSON et al., 1988, "Monoclonal Antibodies Against the Receptor for Epidermal Growth Factor as Potential Anticancer Agents," Cellular and Molecular Biology of Tumors and Potential Clinical Applications, 307-312. (**EXHIBIT 18**)
- 109.MENDELSON, J., December 1997, "Epidermal Growth Factor Receptor Inhibition by a Monoclonal Antibody as Anticancer Therapy," Clin. Cancer Res., 3:2703-2707.
- 110.NAKAO et al., 1983, "Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer-a randomized comparative study by an envelope method," Gan To Kagaku Ryoho, 10: 1146-1159. (**EXHIBIT 19**)

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 17

111. NAKAZATO et al., 1994, "Efficacy of immunotherapy as adjuvant treatment after curative resection of gastric cancer," *The Lancet*, 343:1122-1126 (**EXHIBIT 20**)
112. HIROAKI NANBA and KEIKO KUBO, 1997, "Effect of Maitake D-Fraction on Cancer Prevention," *Annal. N.Y. Acad. Sci.* 833:204-207. (**EXHIBIT 21**)
113. NICOLOSI et al., 1999, "Plasma lipid changes after supplementation with β -glucan fiber from yeast," *Am. J. Clin. Nutr.*, 70:208-212. (**EXHIBIT 22**)
114. OHNO et al., 2000, "Antitumor 1,3- β -Glucan from Cultured Fruit Body of *Sparassis crispa*," *Biol. Pharm. Bull.*, 23(7):866-872. (**EXHIBIT 23**)
115. OLLERT et al., April 1996, "Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells," *Proc. Natl. Acad. Sci. USA*, 93:4498-4503. (**EXHIBIT 24**)
116. OLLERT et al., October 1997, "Mechanisms of in vivo antineuroblastoma activity of human natural IgM," *European Journal of Cancer*, 33(12):1942-1948. (**EXHIBIT 25**)
117. ONIZUKA et al., July 1, 1999, "Tumor Rejected by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor α) Monoclonal Antibody," *Cancer Research*, 59:3128-3133. (**EXHIBIT 26**)

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 18

118. OXFORD TEXTBOOK OF ONCOLOGY, 1995, "Chemotherapy: General Aspects", Peckham, Pinedo and Veronesi, ed., Vol. 1, 447-453 (**EXHIBIT 27**)
119. PATCHEN et al., 1984, "Soluble Polyglycans Enhance Recovery from Cobalt-60-Induced Hemopoietic Injury", Journal of Biological Response Modifiers, 3:627-633.
120. PEAT et al., 1958, "Polysaccharides of Baker's Yeast. Part II. Yeast Glucan", Journal Chem. Soc. Part 1, 3862-3868.
121. RAI, K.R. and GUPTA, N., June 2000, "Monoclonal Antibodies in Chronic Lymphocytic Leukemia," Rev. Clin. Exp. Hematol., 4.2:134-144.
122. REN et al., 1997, "Mechanisms of Anti-Lung Cancer Activity for Monoclonal Antibody to Epidermal Growth Factor Receptor," Disi Junyi Daxue Xuebao, 18(6):560-562 (abstract only). (**EXHIBIT 28**)
123. ROBBINS et al., 1977, "Cholesterol Lowering Effect of Dietary Yeast and Yeast Fractions", Journal of Food Science, 42 (3):694-698.
124. SAITO et al., 1977, "A C-N.M.R.-spectral study of a gel forming, branched (1→3)-β-D-Glucan, (Lentinan) from Lentinus edodes, and its acid-degraded fractions. Structure, and Dependence of Confirmation on the Molecular Weight", Carbohydrate Research, 58:293-305.
125. SASAKI et al., 1976, "Antitumor Activity of Degraded Products of Lentinan: it's Correlation with Molecular Weight", Gann, 67:191-195.

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 19

126.SELJELID et al., 1977, "Glycan Stimulation of Macrophages in Vitro", Experimental Cell Research, 131:121-129.

127.SELJELID et al., 1986, "A water soluble aminated β -1,3-D-glucose derivative caused regression of solid tumors in mice", Bioscience Reports 6:845-852. (**EXHIBIT 29**)

128.SINGH et al., 1974, "Scleroglucan, an antitumor polysaccharide from Sclerotium gluconicum", Carbohydrate Research, 37:245-247.

129.SLOVIN, S.F. et. al., May 1999, "Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man," Proc. Natl. Acad. Sci. USA, 96:5710-5715.

130.SOIFFER et al., 1997, "Administration of R24 Monoclonal Antibody and Low-Dose Interleukin 2 for Malignant Melanoma," Clinical Cancer Research, 3:17-24. (**EXHIBIT 30**)

131.SONG et al., "Yeast glucan and immunotherapy of infectious diseases", Yeast glucan and immunotherapy, chapter 18, 533-545.

132.TORISU et al., 1990, "Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer," Cancer Immunology Immunotherapy, 31(5):261-268. (**EXHIBIT 31**)

133.WILLIAMS et al., 1991, "Development, physicochemical characterization and preclinical efficacy evaluation of a

Applicant : Nai-Kong V. CHEUNG Atty. Dkt. No. : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of SIDS : October 10, 2008
Examiner : Eric Olson
Page : 20

water soluble glucan sulfate derived from *Saccharomyces cerevisiae*," Immunopharmacology 22:139-155 (**EXHIBIT 32**)

134.ZIMMERMAN, J.W., et al., August 21, 1998, "A Novel Carbohydrate-Glycosphingolipid Interaction between a β -(1-3)-Glucan Immunomodulator, PGG-glucan, and Lactosylceramide of Human Leukocytes," J. Biol. Chem., 273(34):22014-22020.

If a telephone interview would be of assistance in advancing prosecution of this application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below. No fee is deemed necessary in connection with the filing of this SIDS. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan/WW

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
e-mail: chank@kitchanlaw.com